January 8, 2014

News stories about doctor shopping and prescription pad pilfering in pursuit of a pain-pill induced high have become commonplace, prompting many legislators and regulators to consider further restrictions on pain medicines like hydrocodone compounds. But there may be a story that’s not being told — that the patients who suffer from chronic pain and need that hydrocodone to reclaim their lives are being stigmatized. The prevalence of pain pill abuse has left in its wake as many as 116 million legitimate pain sufferers who are finding it more difficult to access their therapies.

October 23, 2014

Actavis on Thursday confirmed that the United States Court of Appeals for the Federal Circuit has upheld a lower court ruling that found United States Patent No. 7,704,984 (the '984 Patent) to be valid.

October 22, 2014

Pfizer last week announced that the Food and Drug Administration approved a revised label for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII, to include abuse-deterrence studies. 

 

October 17, 2014

Pillar Rock USA recently introduced JetRyte, a nutritional supplement formulated to combat jet lag. 

October 17, 2014

Purdue Pharma has launched an awareness campaign to address specific knowledge gaps among pharmacists related to its Schedule III extended-release transdermal opioid, Butrans.

October 16, 2014

 Kaz on Wednesday launched the new Febreze Air Purifier. 

October 15, 2014

The big story in the digestives space is the switch and launch in May of Pfizer’s Nexium 24HR. In a little more than 10 weeks on the shelf, the brand has generated $53.6 million in sales across total U.S. multi-outlets for the 52 weeks ended Aug. 10, according to IRI. 

October 13, 2014

Church & Dwight on Monday announced the launch of Replens Silky Smooth.

October 10, 2014

The Drug Enforcement Administration’s final rule moving hydrocodone combination products from Schedule III to the more-restrictive Schedule II officially went into effect on Monday. 

October 9, 2014

Purdue Pharma on Thursday announced the launch of a new dosage strength of 7.5 mcg/hour for its Butrans (buprenorphine) transdermal system CIII, bringing the total number of strengths offered by the company to five.

October 9, 2014

Expanding on its voluntary ingredient disclosure program, SC Johnson will begin disclosing air care fragrance ingredients present at the highest concentrations down to .09% of the product formula. 

October 8, 2014

Teva Pharmaceutical Industries on Wednesday announced the initiation of a rolling new drug application submission for hydrocodone bitartrate extended-release tablets.

October 7, 2014

Actavis and Durata Therapeutics on Monday announced that they have entered into a definitive merger agreement.

October 6, 2014

Mylan announced the launch of its lamivudine and zidovudine tablets USP, in 150-mg dosage strength.

October 2, 2014

Seroyal on Wednesday announced the Canadian release of Genestra Brands Statin Care, a balanced nutritional supplement formulated to provide nutritional support for patients taking statin medications.

September 30, 2014

Par Pharmaceutical on Tuesday announced that it has started shipping amlodipine and valsartan tablets in all four dosage strengths.

September 30, 2014

Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain. 

September 26, 2014

Actavis on Friday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine transdermal system, a generic version of Butrans from Purdue Pharma. 

September 26, 2014

Camber Pharmaceuticals announced the launch of raloxifene hydrochloride, USP tablets in 60-mg dosage strengths.

September 26, 2014

As part of its new Women’s Wellness initiative, Schnucks Pharmacies has announced that four different oral breast cancer medications (Letrozole, Megestrol, Anastrozole and Tamoxifen) will be available for $9 with a valid prescription.

September 24, 2014

Dr. Reddy's Labs on Wednesday announced the launch of levalbuterol inhalation solution, USP in 0.31-mg, 0.63-mg and 1.25-mg unit-dose vials.

September 24, 2014

Perfecta Products is further expanding its portfolio with the new Zim's Advanced Vapor Rub, available in both a traditional jar and a tube with no-mess applicator.

September 17, 2014

Mission Pharmacal on Tuesday participated in a White House Industry Leadership Roundtable discussion on ways to curb emissions of hydrofluorocarbons. 

September 16, 2014

The Food and Drug Administration on Tuesday announced approval for Movantik (naloxegol), a treatment for opioid-induced constipation in adults.